Anti-Human HLA-I Recombinant Antibody (C3B3) (CAT#: TAB-097CT)

Figure 1 Effect of C3B3 on cell signaling pathways.

RPMI 8226 cells were incubated with C3B3 (1 mg/ml) for 24 h and cytospin specimens were stained with Alexa 488-labeled phalloidin for the detection of actin. The specimens were examined by confocal microscopy. Scale bar, 10 mm.

Ikegame, A., Ozaki, S., Tsuji, D., Harada, T., Fujii, S., Nakamura, S., ... & Abe, M. (2012). Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia, 26(9), 2124.

Figure 2 Effect of C3B3 on tumor development in vivo.

Each SP cell-derived tumor in SCID mice was removed on week 8 and examined by flow cytometric SP analysis. The data shown are representative of four individual mice.

Ikegame, A., Ozaki, S., Tsuji, D., Harada, T., Fujii, S., Nakamura, S., ... & Abe, M. (2012). Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia, 26(9), 2124.

Figure 3 Effect of C3B3 on tumor development in vivo.

These SP tumors in SCID mice were examined by immunohistochemical staining of Ki-67. The specimen was examined by microscopy. Scale bar, 100 mm.

Ikegame, A., Ozaki, S., Tsuji, D., Harada, T., Fujii, S., Nakamura, S., ... & Abe, M. (2012). Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia, 26(9), 2124.

Figure 4 SP cells derived from RPMI 8226 were treated with C3B3 (1 mg/ml) for 48 h.

C3B3-treated SP cells (5 × 10⁶ cells) were transplanted subcutaneously in the right flank, whereas untreated SP cells were inoculated in the left flank of four SCID mice. Tumor sizes of both sides were measured weekly, and tumor volumes were calculated as described in Materials and Methods (mean±s.d. of four mice, *P<0.05).

Ikegame, A., Ozaki, S., Tsuji, D., Harada, T., Fujii, S., Nakamura, S., ... & Abe, M. (2012). Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia, 26(9), 2124.